ANI Pharmaceuticals, Inc. (ANIP)
71.47
+0.41
(+0.58%)
USD |
NASDAQ |
Nov 13, 16:00
71.47
0.00 (0.00%)
After-Hours: 19:59
ANI Pharmaceuticals Enterprise Value : 1.798B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 1.798B |
| November 11, 2026 | 1.799B |
| November 10, 2026 | 1.803B |
| November 09, 2026 | 1.723B |
| November 06, 2026 | 1.715B |
| November 05, 2026 | 1.765B |
| November 04, 2026 | 1.812B |
| November 03, 2026 | 1.826B |
| November 02, 2026 | 1.789B |
| October 30, 2026 | 1.820B |
| October 29, 2026 | 1.846B |
| October 28, 2026 | 1.813B |
| October 27, 2026 | 1.801B |
| October 26, 2026 | 1.833B |
| October 23, 2026 | 1.834B |
| October 22, 2026 | 1.860B |
| October 21, 2026 | 1.825B |
| October 20, 2026 | 1.835B |
| October 19, 2026 | 1.833B |
| October 16, 2026 | 1.826B |
| October 15, 2026 | 1.826B |
| October 14, 2026 | 1.778B |
| October 13, 2026 | 1.793B |
| October 12, 2026 | 1.856B |
| October 09, 2026 | 1.863B |
| Date | Value |
|---|---|
| October 08, 2026 | 1.819B |
| October 07, 2026 | 1.818B |
| October 06, 2026 | 1.809B |
| October 05, 2026 | 1.833B |
| October 02, 2026 | 1.824B |
| October 01, 2026 | 1.842B |
| September 30, 2026 | 1.835B |
| September 29, 2026 | 1.903B |
| September 28, 2026 | 1.954B |
| September 25, 2026 | 1.935B |
| September 24, 2026 | 1.935B |
| September 23, 2026 | 1.944B |
| September 22, 2026 | 2.024B |
| September 21, 2026 | 2.046B |
| September 18, 2026 | 1.984B |
| September 17, 2026 | 1.967B |
| September 16, 2026 | 1.925B |
| September 15, 2026 | 1.891B |
| September 14, 2026 | 1.852B |
| September 11, 2026 | 1.847B |
| September 10, 2026 | 1.876B |
| September 09, 2026 | 1.859B |
| September 08, 2026 | 1.848B |
| September 04, 2026 | 1.871B |
| September 03, 2026 | 1.888B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Eli Lilly & Co. | 1.388T |
| Supernus Pharmaceuticals, Inc. | 1.378B |
| Ocular Therapeutix, Inc. | 930.28M |
| Corcept Therapeutics, Inc. | 7.700B |
| Veru, Inc. | 13.04M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 32.72M |
| Revenue (Quarterly) | 290.78M |
| Total Expenses (Quarterly) | 258.06M |
| EPS Diluted (Quarterly) | 1.510 |
| Gross Profit Margin (Quarterly) | 54.92% |
| Profit Margin (Quarterly) | 11.25% |
| Earnings Yield | 7.01% |
| Operating Earnings Yield | 10.27% |
| Normalized Earnings Yield | 6.385 |